Key result
IGF-I up-regulates IGFBP-5 synthesis in aortic smooth muscle cells by boosting promoter activity ~3.5-fold.
IGF-I specifically up-regulates IGFBP-5 synthesis in aortic smooth muscle cells via transcriptional activation, providing insight into vascular smooth muscle cell regulation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in aortic smooth muscle cells; leaves open relevance to human vascular disease.
Previous studies have shown that porcine aortic smooth muscle cells (SMCs) secrete two insulin-like growth factor-binding proteins (IGFBP), IGFBP-2 and -4, and that these IGFBPs modulate IGF-I-stimulated SMC proliferation and migration. In this study we demonstrate that porcine SMCs express IGFBP-5 mRNA and synthesize and secrete the protein. In this cell type, the biosynthesis of IGFBP-5 is up-regulated by IGF-I. This increase in IGFBP-5 synthesis is accompanied by an increase in the steady-state mRNA levels. The induction of IGFBP-5 mRNA by IGF-I is time- and dose-dependent and requires de novo protein synthesis. IGF-II and insulin also increase IGFBP-5 mRNA levels at high doses. An IGF-I analog with normal affinity for the IGF-I receptor but reduced affinity for IGFBPs evokes a similar increase. Another analog that binds to IGFBPs but not to the receptor has no effect, indicating that this effect of IGF-I is mediated through the IGF-I receptor. The IGF-I-induced IGFBP-5 gene expression is cell type-specific because IGF-I had no such effect in other cell types examined. Nuclear run-on assays revealed that IGF-I increased transcription rate of the IGFBP-5 gene, while IGF-I did not change the IGFBP-5 mRNA stability. Furthermore, the IGFBP-5 promoter was 3.5-fold more active in directing expression of the luciferase reporter gene in IGF-I-treated aortic SMCs as compared to control cells, whereas the luciferase activity remained the same in control- and IGF-I-treated fibroblasts. These results suggest that IGF-I up-regulates IGFBP-5 synthesis by transcriptionally activating the IGFBP-5 gene in aortic SMCs.
No takes yet. Share an insight, caveat, or question.
Clemmons et al. (2021) studied this question. Insulin-like Growth Factor-I (IGF-I) vs. Control cells was evaluated on IGFBP-5 synthesis and mRNA levels. IGF-I up-regulates IGFBP-5 synthesis by transcriptionally activating the IGFBP-5 gene in aortic smooth muscle cells, with the promoter being 3.5-fold more active in treated cells.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: